Major Depression
Conditions
Keywords
major depression, DU 125530, Treatment depression, Latency antidepressant
Brief summary
The purpose of this study is to examine whether the speed of the clinical antidepressant action of fluoxetine can be accelerated by administering DU125530 a full 5-HT1A antagonist.
Detailed description
SSRI acts by blocking the serotonin transporter (5-HT), increasing the availability of serotonin at the synaptic cleft averting its reuptake. The increment of serotonin activates 5-HT1A presynaptic autoreceptors, resulting in a modulation in the release of serotonin by the presynaptic neuron. It is proposed that 5-HT1A receptor antagonism could accelerate the clinical effect of antidepressants by preventing this negative feedback.Preclinical data obtained with selective 5-HT1A antagonists, such as pindolol, and with mice lacking 5-HT1a receptors supports this hypothesis. Results on partial antagonists (pindolol) are conclusive in accelerating SSRI. It is reasonable to call into question whether a total antagonism of 5-HT1a receptors could imply a more rapid antidepressant response. To test this hypothesis we conducted a double blind, randomised, controlled trial with DU 123550 added to fluoxetine 20 mg/day
Interventions
DRUGDU125530
20mg/twice a day
DRUGPlacebo
Similar pill as active comparator twice a day
Sponsors
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Consecutive eligible patients aged 18 to 70 * Diagnosis of unipolar major depression using DSM-IV criteria with moderate to severe symptoms (score e 18 on the Hamilton Depression Rating Scale-HDRS- of 17 items). * There was a wash-out of 1 week of any antidepressant drug (specifically 28 days for fluoxetine) prior entering the study. * Written informed consent was obtained from all participants.
Exclusion criteria
* Concurrent psychiatric disorders (DSM IV axis I, II cluster A or B) * Failure to respond to drug treatment in current depressive episode * Previous resistance to SSRIs or other antidepressant drug * Suicide risk score e 3 on the HDRS. * Participation in other drug trials within the previous month * Presence of delusions or hallucinations * History of substance abuse (including alcohol) in the past three months * Pregnancy or lactation * Organic brain disease or history of seizures * Serious organic illnesses such as hypo or hyperthyroidism,cardiac arrhythmias, asthma, diabetes mellitus. * Myocardial infarction in the past 6 month * Frequent or severe allergic reactions * Concomitant use of other psychotropic drugs (benzodiazepines were allowed), lockers or catecholamine-depleting agents * Current structured psychotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Scores on Hamilton Depression Rating Scale | 8 time points through 8 weeks |
Countries
Spain
Outcome results
None listed